One of the most poorly publicised and understood areas of global pharma is falsified and counterfeit medicines. Historically, the focus on this topic has been on low value – high volume medicines, including anti-malarials. However, today even monoclonal antibodies (mAbs) have been falsified throughout Europe and the US.

Change is afoot with the implementation of the EU Falsified Medicines Directive, which is the focus of a discussion by key members of the IPAV team and longstanding industrial collaborator, Graham Smith, Aegate Ltd.

The piece published in the Journal of Generic Medicines, discusses the forthcoming regulation and its impact on all healthcare stakeholders, in particular, pharmaceutical distribution. Despite his modesty, Graham is the ‘FMD oracle’ and IPAV are proud to collaborate with him and the Aegate team.

We look forward to supporting our clients swiftly achieve FMD compliance, with critical strategic partners, including Aegate Ltd.

Congratulations to the authors on a timely and authorities piece.